Coloplast Medical Device Company Intelligence Report

Additional Information

Coloplast develops and manufactures ostomy devices, urology products, continence care devices, advanced wound care and skin care products, as follows:

Ostomy Care includes products for people whose intestinal outlet has been surgically-rerouted through the abdominal wall. The company’s key brands within this field include SenSura, Assura, Easiflex, Alterna and Corsinel;
Urology, including products for people suffering from diseases of, and damage to, the kidneys, the urinary system or the male reproductive system. Key brands include Minitape, Restorelle, Dormia, Titan, KiWee, Aris, Novasilk, Elefant, Virtue, Altis, Suspend, Exair and Axis;
Continence Care for people suffering from diseases of, and damage to, the urinary system. Key brands include SpeediCath, EasiCath, SelfCath, Simplax, Aquadry, Conveen, SpeediBag and Peristeen; and
Wound and Skin Care products include dressings for the treatment of chronic wounds and skin care products for prevention and treatment. Key brands include Biatain, Alione, Comfeel, Physiotulle, SeaSorb, Sween, Critic-Aid and InterDry

In June 2006, Coloplast purchased Mentor’s urology unit, which enabled it to expand its existing continence care portfolio and gain new products that address general and surgical urology. This acquisition also moved Coloplast to the leading position in the urology and continence care market segments in which it participates. Through the acquisition, Coloplast also gained Mills Biopharmaceuticals, Mentor’s brachytherapy division, but it sold this business to Core Oncology in June 2007.

In April 2007, Coloplast sold its Breast Care unit, which manufactured external breast forms and post-mastectomy lingerie and swimwear, as part of its strategy to focus on its Ostomy, Urology, Continence, and Wound and Skin Care units.

To further enhance its urology portfolio, Coloplast acquired assets related to the Levera Male Incontinence Therapy - a sling therapy designed to address symptoms of male stress urinary incontinence (SUI) - from Caldera Medical in November 2007.

More recently, Coloplast expanded its urology portfolio and expanded its geographic coverage in the US with the acquisition of Mpathy Medical Devices, a developer of less invasive surgical solutions for the treatment of female stress urinary incontinence and pelvic organ prolapse.

In March 2011, Coloplast completed the transfer of the majority of production from Denmark to lower-cost Hungary and China. Approximately 85% of the company’s products are now produced in Hungary and China.

Coloplast markets and sells its products and services globally. The majority of its revenue is generated in Europe, which accounted for 73% of the company’s DKr10,172 million of total sales in fiscal 2011. At the end of September 2011, Coloplast employed more than 7,350 people.

Coloplast’s major shareholders are members of the Louis-Hansen family, which hold approximately 31% of the share capital and 55% of the votes in Coloplast.

This company report provides

Overview
Key contact information
Introduction to the company and its current activities
Summary of its financial performance
Who are the company’s major competitors?
Key recent events in an “at a glance” format

Financial Review Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
Table providing in-depth five-year financial analysis
Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Products
Core product areas, key brands, product approvals and launches
Research and Development How much has been invested in R&D?
Where is the research based?
What alliances and agreements does the company have and with whom?

Manufacturing and Distribution Identifying the company’s manufacturing locations
Sales and marketing facilities

Agreements With whom has the company reached agreements and what do they involve?
Key contracts awarded

Mergers, Acquisitions, Minority Investments and Divestments

Litigation

Key Corporate Events